XIANG YANQUN
Gemcitabine + cisplatin (GP)(XIANG YANQUN)은 Nasopharyngeal Cancinoma (NPC) 표적 치료제로, Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer 영역에서 개발·상용화 중입니다. 작용기전: target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 44.4% (ClinicalTrials.gov NCT02807636). 차별점: unique disposition of simvastatin rather than enzyme or transporter inhibition.
Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer
Recruiting
CAR-T development and immunotherapy target identification
vedotin plus PD-1 blockade and gemcitabine/cisp
humanized GPVI (hGP6 tg/tg ) mouse model, we show that high-affinity anti-human GPVI IgGs (Emf1 K D 0
unique disposition of simvastatin rather than enzyme or transporter inhibition
target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway
Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor
DNA damage-related proteins including phosphorylated histone H2AX(γ-H2AX) and the tumor suppressor p53(p53), apoptosis-relat
biomarkers, enhanced trial matching, and scalable cohort identification
downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
XIANG YANQUN
Gemcitabine + cisplatin (GP)(XIANG YANQUN)은 Nasopharyngeal Cancinoma (NPC) 표적 치료제로, Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer 영역에서 개발·상용화 중입니다. 작용기전: target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 44.4% (ClinicalTrials.gov NCT02807636). 차별점: unique disposition of simvastatin rather than enzyme or transporter inhibition.
Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer
Recruiting
CAR-T development and immunotherapy target identification
vedotin plus PD-1 blockade and gemcitabine/cisp
humanized GPVI (hGP6 tg/tg ) mouse model, we show that high-affinity anti-human GPVI IgGs (Emf1 K D 0
unique disposition of simvastatin rather than enzyme or transporter inhibition
target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway
Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor
DNA damage-related proteins including phosphorylated histone H2AX(γ-H2AX) and the tumor suppressor p53(p53), apoptosis-relat
biomarkers, enhanced trial matching, and scalable cohort identification
downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.